New research: A mini-version of antibodies, called nanobodies, could eventually be used to treat neurocognitive disorders.
Proteins called antibodies help the immune system find and attack foreign pathogens. Mini versions of antibodies, called nanobodies — natural compounds in the blood of animals such as llamas and sharks — are being studied to treat autoimmune diseases and cancer. Now, Johns Hopkins Medicine researchers have helped develop a nanobody capable of getting through the tough exterior of brain cells and untangling misshapen proteins that lead to Parkinson’s disease, Lewy body dementia, and other neurocognitive disorders caused by the damaging protein.
“The success of PFFNB2 in binding harmful alpha-synuclein clumps in increasingly complex environments indicates that the nanobody could be key to helping scientists study these diseases and eventually develop new treatments” says Mao, associate professor of neurology.
Visible Legacy Comment
The research, published July 19, 2022 in Nature Communications, was a collaboration between Johns Hopkins Medicine researchers, led by Xiaobo Mao, Ph.D., and scientists at the University of Michigan, Ann Arbor. It has led to a recently released technology for license. Corporate technology licensing professionals can view the context of this available technology in Visible Legacy.
- Caption: Disulfide Bond-free and Fibril-specific Nanobodies Prevent the Prion-like α-synuclein Spreading
- USF CUTR receives $3.5M contract from the U.S. Department of Energy
- WSU Researchers develop recyclable composites
- Check this out: Researchers Design New Approach to Creating Antibody Libraries
- Researchers find superconducting material that could someday power quantum computers
- Driving Revolutionary Advances in Cancer Treatment